Pharma BD Deal Intelligence

Gedeon Richter Plc. / Mayne Pharma Group Limited

2026 · Acquisition/Merger · Pending

Mayne Pharma entered a scheme implementation deed under which Hungary's Gedeon Richter will acquire 100% of Mayne Pharma for A$6.40 per share in cash, valuing the company at approximately A$604 million. The price represents a 99.4% premium to Mayne Pharma's 16 November closing price and a 124% premium to its 30-day volume weighted average price. The Mayne Pharma board unanimously recommends shareholders vote in favour of the scheme absent a superior proposal. Richter intends to fund the acquisition entirely from internal cash resources, so the scheme carries no financing condition. The scheme remains subject to customary conditions including shareholder approval at the scheme meeting and completion of Mayne Pharma's previously announced sale of its international business segment to Evaris Pharma. The shareholder vote is provisionally scheduled for late January 2027, with the second court hearing and implementation targeted for mid-to-late March 2027.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →